RIGI and infection: Future studies to investigate if prophylactic LNP-DI290 application is protective, if administration at a later time point after infection provides protection from infection, or to benchmark DI290 antiviral activity compared with other RIG-I agonists is warranted but a different approach and animal model may be necessary.